BMS Second Quarter Results: Total revenue rose 61% to $1.65 billion.

Read: BMS Q2 2020 Results: Revenue was higher than expected, reaching $10.1 billion, up 61%.
, Aug. 6, BMS reported better-than-expected revenue for the second quarter of 2020, up 61 percent to $10.1 billion, with U.S. revenue up 77 percent and international market revenue of $3.6 billion up 40 percent.
this reflects strong product sales, a continued product line and strong operating results.
revenue was in line with estimates, and the COVID-19 pandemic had a negative impact on sales of about $600 million.
revenue growth was driven primarily by the completion of the acquisition of Celgene on November 20, 2019, which resulted in a broader portfolio and product line.
earnings per share (EPS) were $1.63 in the second quarter, up from expectations of $1.48.
BMS has raised its full-year EPS guidance to $6.1-6.25 from $6.2.
full-year revenue guidance of $40.5 billion to $42 billion.
drug sales, anticoagulants Eliquis sales rose 21% to $4.804 billion in the first half of the year, while opdivo sales of anti-PD-1 therapy fell 6% to $3.419 billion, with sales of $1.653 billion in the second quarter. 9%, down 9%; sales of anti-inflammatory drug Orencia were up 3% at $1.464 billion; sales of the leukemia drug Sprycel were $1.032 billion, up 3% from $1.032 billion; and sales of anti-CTLA-4 therapy Yervoy were $765 million, up 2%. Several oncology drugs acquired
's acquisition of New Base performed well: two immunomodulators, Revlimid sales rose 10 percent to $5,799 million, Pomalyst/Imnovid sales rose 25 percent to $1.458 billion, and chemotherapy drug Abraxane added 2 percent to $608 million.
, several new products acquired by the acquisition of New Base will also be drivers of BMS's recent sales, including Reblozyl, Inrebic and Zeposia. among
, Reblozyl is the world's first erythropoietic mature agent, approved in the United States and the European Union for the treatment of beta thalassemia/myelomed hyperplasia syndrome-related anemia; Inrebic is the first new bone marrow fibrosis drug in nearly a decade; and Zeposa has been approved for multiple sclerosis in the United States and the European Union.
Second Quarter Product and Pipeline Update Highlights: Cardiovascular: Eliquis' Compound Patent (US6967208) and Formula Patent (US9326945) were upheld by u.S. District Court.
Oncology: Opdivo received three FDA approvals, Pomalyst received an FDA approval, BCMA CAR-T cell therapy ide-cel filed a listing application in the United States.
Reblozyl was approved by the European Union, and ide-cel, CD19 CAR-T cell therapy Liso-cel, and the leukemia drug CC-486 were accepted in the Eu.
Immunology: Zeposia is listed in the United States and approved in the European Union for the clinical success of stage III of the treatment of ulcerative colitis.
the latest data from Early AMPLE, a phase-of-the-art exploratory biomarker study at Orencia IV, reinforces Orencia's improved and lasting clinical remission in patients with autoantibodies-positive moderate to severe early rheumatoid arthritis.
Source: 1, Bristol Myers Squibb Reports Second Quarter 2020 Financial Results2, Analysts to Bristol Myers Squibb: Can I-O hit Opdivoly return to growth?